Natural autoantibodies raised by humoral immune response to cancer can be exploited to identify potential tumor-associated antigens (TAAs), and might constitute new putative prognostic and/or diagnostic biomarkers. Here we describe how sera from tumor patients can be used to identify TAAs by screening antibody immunoreactivity against the cancer proteome resolved by two-dimensional gel electrophoresis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-4939-3338-9_2 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!